샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784050

세계의 원발성 담즙성 담관염 치료제 시장

Primary Biliary Cholangitis Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 273 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

원발성 담즙성 담관염 치료제 세계 시장은 2030년까지 11억 달러에 달할 전망

2024년에 7억 7,160만 달러로 추정되는 원발성 담즙성 담관염 치료제 세계 시장은 분석 기간인 2024-2030년에 CAGR 6.7%로 성장하여 2030년에는 11억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 1차 의약품은 CAGR 7.8%를 기록하며 분석 기간 종료시에는 8억 240만 달러에 달할 것으로 예측됩니다. 2차 의약품 부문의 성장률은 분석 기간 동안 CAGR 4.3%로 추정됩니다.

미국 시장은 2억 1,020만 달러로 추정, 중국은 CAGR 10.7%로 성장 예측

미국의 원발성 담즙성 담관염 치료제 시장은 2024년에 2억 1,020만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 10.7%로 2030년까지 2억 3,860만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.2%와 6.6%로 예측됩니다. 유럽에서는 독일이 CAGR 4.4%로 성장할 것으로 예측됩니다.

원발성 담즙성 담관염(PBC) 치료제 세계 시장 - 주요 동향 및 촉진요인 정리

원발성 담즙성 담관염(PBC) 치료제 수요가 증가하는 이유는?

원발성 담즙성 담관염(PBC)은 담관의 점진적인 파괴를 특징으로 하는 만성 자가면역성 간질환으로 간 손상, 섬유화, 심한 경우 간경변증을 유발합니다. 자가면역질환의 유병률 증가는 PBC에 대한 인식이 높아지고 진단이 개선되면서 효과적인 치료제에 대한 수요를 촉진하고 있습니다. 현재 치료 옵션은 질병의 진행을 늦추고, 피로, 가려움증 등의 증상을 완화하며, 간부전을 예방하는 데 주안점을 두고 있습니다. 우르소데옥시콜산(UDCA)은 수십 년 동안 1차 선택 약물이었지만, 오베티콜산(OCA)과 같은 새로운 약물이 UDCA로 충분한 효과를 얻지 못하는 환자들을 위한 2차 선택 약품으로 등장했습니다. 또한, 피브라아제, 면역조절제, 항섬유화제 등 새로운 치료 표적에 대한 연구가 활발히 진행되고 있어 PBC 환자들에게 새로운 희망을 주고 있습니다. 맞춤형 의료가 강조되고, 치료 방침 결정에 바이오마커가 포함되면서 PBC 치료제의 상황은 더욱 변화하고 있습니다. 의료 서비스 제공자들이 보다 효과적이고 표적화된 치료법을 모색하는 가운데, PBC 치료제 시장은 크게 성장할 것으로 보입니다.

PBC 치료제의 성장에 영향을 미치는 과제는 무엇인가?

치료 옵션의 발전에도 불구하고, PBC 치료제 시장은 그 잠재력을 충분히 발휘하지 못하는 몇 가지 도전에 직면해 있습니다. 주요 우려 사항 중 하나는 OCA와 같은 신약의 높은 가격 때문에 특히 중저소득 국가에서는 환자 접근성이 제한될 수 있다는 점입니다. 또한, 이 질환의 희귀성으로 인해 대규모 임상시험 수행에 어려움을 겪고 있으며, 의약품 개발 및 규제 당국의 승인 절차가 지연되고 있습니다. 또한, UDCA는 많은 환자에게 효과적이지만, PBC 환자의 상당수는 현재 사용 가능한 치료법에 반응하지 않기 때문에 다른 치료법이 필요합니다. PBC는 종종 쇼그렌 증후군이나 류마티스 관절염과 같은 다른 자가면역질환과 동반되는 경우가 많아 치료 프로토콜이 복잡해집니다. 또한, 환자의 장기적인 치료 순응도는 질환의 진행을 관리하는 데 매우 중요하지만, 부작용이나 즉각적인 증상 완화로 인해 치료를 중단하는 환자도 많습니다. 이러한 과제를 해결하기 위해서는 연구에 대한 지속적인 투자, 구매하기 쉬운 가격 개선, 혁신적인 치료제 개발을 가속화하기 위한 제약사와 규제당국과의 협력 강화가 필요합니다.

기술 혁신과 의약품 개발은 PBC 치료를 어떻게 발전시키고 있는가?

혁신적인 약물 개발과 바이오테크놀러지의 발전은 PBC 치료제의 상황을 바꾸고 질병 관리와 환자 결과를 개선하고 있습니다. FXR 작용제와 같은 담즙산 수용체 작용제의 출현으로 UDCA에 반응하지 않는 환자의 치료 옵션이 확대되고 있습니다. 항섬유화제나 면역요법 연구도 진행 중이며, 간염이나 섬유화를 직접 타겟으로 하는 질병 변형 치료의 가능성도 있습니다. 또한, 바이오마커 연구의 발전으로 조기 진단과 맞춤 치료 전략이 가능해져 질병의 진행과 치료 반응을 더 잘 모니터링할 수 있게 되었습니다. AI를 활용한 Drug Discovery 플랫폼은 새로운 치료 타겟 발굴을 가속화하고, 임상시험과 의약품 허가까지 소요되는 시간을 단축하고 있습니다. 원격의료 및 원격 환자 모니터링과 같은 디지털 건강 도구의 통합은 환자의 순응도를 높이고 의료 서비스 제공자에게 실시간 데이터를 제공함으로써 질병 관리를 더욱 개선하고 있습니다. 이러한 기술 혁신이 진행됨에 따라, PBC 치료제는 보다 표적화되고 효과적인 치료제가 되어 환자들에게 전반적인 표준 치료의 질을 향상시킬 수 있습니다.

원발성 담즙성 담관염 치료제 시장의 성장 원동력은?

원발성 담즙성 담관염 치료제 시장의 성장은 자가면역성 간질환 유병률 증가, 희귀질환 연구에 대한 투자 증가, 시장 개척의 진전 등 여러 요인에 의해 주도되고 있습니다. 희귀질환에 대한 정부의 노력과 자금 지원 확대는 제약사들의 PBC 치료제 개발을 촉진하고 시장 개척을 가속화하고 있습니다. 맞춤형 의료와 바이오마커에 기반한 치료 접근법이 확대되고 있는 것도 PBC 치료제의 효능을 더욱 높이고 있습니다. 또한, 첨단 진단 도구의 가용성이 높아짐에 따라 조기 발견율이 향상되어 적시에 개입하고 환자의 예후를 개선할 수 있습니다. 디지털 헬스 솔루션과 환자 중심 케어 모델의 부상도 시장 확대에 기여하고 있으며, 보다 효율적인 질병 관리 전략을 제공하고 있습니다. PBC 치료제 시장은 만성 간질환을 앓고 있는 환자들에게 새로운 개선책을 제공함으로써 인식과 치료 옵션이 계속 발전함에 따라 큰 성장이 예상됩니다.

부문

약물 유형(1차 치료제, 2차 치료제), 유통 채널(병원 약국, 드럭스토어·소매 약국, 온라인 약국)

조사 대상 기업 사례

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Calliditas Therapeutics AB
  • CymaBay Therapeutics
  • Escient Pharmaceuticals
  • Gannex Pharma
  • GENFIT
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc(GSK)
  • Glenmark Pharmaceuticals
  • Intercept Pharmaceuticals
  • Ipsen Pharma
  • Lupin Limited
  • Mirum Pharmaceuticals
  • Mylan(now part of Viatris)
  • Nanjing Chia-tai Tianqing Pharmaceutical
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Primary Biliary Cholangitis Therapeutics Market to Reach US$1.1 Billion by 2030

The global market for Primary Biliary Cholangitis Therapeutics estimated at US$771.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Primary Drug, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$802.4 Million by the end of the analysis period. Growth in the Secondary Drug segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$210.2 Million While China is Forecast to Grow at 10.7% CAGR

The Primary Biliary Cholangitis Therapeutics market in the U.S. is estimated at US$210.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$238.6 Million by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Primary Biliary Cholangitis (PBC) Therapeutics Market - Key Trends & Drivers Summarized

Why Is There an Increasing Demand for Primary Biliary Cholangitis (PBC) Therapeutics?

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of bile ducts, leading to liver damage, fibrosis, and, in severe cases, cirrhosis. The increasing prevalence of autoimmune diseases, coupled with the rising awareness and improved diagnosis of PBC, has fueled demand for effective therapeutics. Current treatment options primarily focus on slowing disease progression, reducing symptoms such as fatigue and pruritus, and preventing liver failure. Ursodeoxycholic acid (UDCA) has been the first-line therapy for decades, but newer drugs such as obeticholic acid (OCA) have emerged as second-line options for patients who do not respond adequately to UDCA. Additionally, research into novel therapeutic targets, including fibrates, immunomodulators, and anti-fibrotic agents, is gaining momentum, offering new hope for PBC patients. The growing emphasis on personalized medicine and the integration of biomarkers in treatment decisions are further shaping the landscape of PBC therapeutics. As healthcare providers seek more effective and targeted treatments, the PBC therapeutics market is set to witness substantial growth.

What Challenges Are Impacting the Growth of PBC Therapeutics?

Despite advancements in treatment options, the PBC therapeutics market faces several challenges that hinder its full potential. One of the primary concerns is the high cost of newer medications such as OCA, which can limit patient accessibility, particularly in low- and middle-income countries. The rarity of the disease also poses a challenge in conducting large-scale clinical trials, leading to slower drug development and regulatory approval processes. Additionally, while UDCA is effective for many patients, a significant portion of individuals with PBC remain non-responsive to available therapies, necessitating alternative treatment options. Another challenge lies in disease management, as PBC often coexists with other autoimmune conditions such as Sjogren’s syndrome and rheumatoid arthritis, complicating treatment protocols. Furthermore, patient adherence to long-term therapy is crucial for managing disease progression, yet many individuals discontinue treatment due to side effects or lack of immediate symptom relief. Addressing these challenges requires continued investment in research, improved affordability, and greater collaboration between pharmaceutical companies and regulatory bodies to accelerate the development of innovative treatments.

How Are Technological Innovations and Drug Development Advancing PBC Treatment?

Innovative drug development and advancements in biotechnology are transforming the landscape of PBC therapeutics, improving disease management and patient outcomes. The emergence of bile acid receptor agonists, such as FXR agonists, is expanding treatment options for patients who are non-responsive to UDCA. Research into antifibrotic agents and immunotherapies is also progressing, offering potential disease-modifying treatments that target liver inflammation and fibrosis directly. Additionally, advancements in biomarker research are enabling early diagnosis and personalized treatment strategies, allowing for better monitoring of disease progression and response to therapy. AI-driven drug discovery platforms are accelerating the identification of novel therapeutic targets, reducing the time required for clinical trials and regulatory approvals. The integration of digital health tools, such as telemedicine and remote patient monitoring, is further improving disease management by enhancing patient adherence and providing real-time data for healthcare providers. As these innovations continue, PBC therapeutics are becoming more targeted, effective, and accessible, improving the overall standard of care for patients.

What Is Driving the Growth of the Primary Biliary Cholangitis Therapeutics Market?

The growth in the primary biliary cholangitis therapeutics market is driven by several factors, including the rising prevalence of autoimmune liver diseases, increasing investment in rare disease research, and advancements in targeted drug development. The expansion of government initiatives and funding for orphan diseases has encouraged pharmaceutical companies to develop novel PBC therapies, accelerating market growth. The growing adoption of personalized medicine and biomarker-based treatment approaches is further enhancing the effectiveness of PBC therapeutics. Additionally, the increasing availability of advanced diagnostic tools is improving early detection rates, leading to timely interventions and better patient outcomes. The rise of digital health solutions and patient-centric care models is also contributing to market expansion, providing more efficient disease management strategies. As awareness and treatment options continue to evolve, the PBC therapeutics market is expected to witness significant growth, offering new and improved solutions for patients suffering from this chronic liver disease.

SCOPE OF STUDY:

The report analyzes the Primary Biliary Cholangitis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Primary Drug, Secondary Drug); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Calliditas Therapeutics AB
  • CymaBay Therapeutics
  • Escient Pharmaceuticals
  • Gannex Pharma
  • GENFIT
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Glenmark Pharmaceuticals
  • Intercept Pharmaceuticals
  • Ipsen Pharma
  • Lupin Limited
  • Mirum Pharmaceuticals
  • Mylan (now part of Viatris)
  • Nanjing Chia-tai Tianqing Pharmaceutical
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Primary Biliary Cholangitis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Autoimmune Liver Disorders Throws the Spotlight on Unmet Needs in PBC Treatment
    • Expansion of Diagnostic Screening Programs Drives Early Detection and Intervention in PBC Cases
    • Growing Acceptance of Ursodeoxycholic Acid (UDCA) as First-Line Therapy Sustains Market Stability in Early-Stage Management
    • Development of Second-Line Therapeutics for UDCA Non-Responders Strengthens Business Case for Advanced Treatment Options
    • Emergence of Farnesoid X Receptor (FXR) Agonists Spurs Innovation in Mechanism-Targeted Drug Development
    • Rising Focus on Bile Acid Modulation Pathways Accelerates Research in Novel Small Molecule Therapies
    • Increased Investment in Rare and Orphan Disease Drug Pipelines Expands Addressable Market for PBC Therapeutics
    • Advancements in Biomarker Discovery Enhance Patient Stratification and Personalized Treatment Strategies
    • Integration of AI and Machine Learning in Drug Discovery Platforms Propels Precision Medicine Approaches in PBC
    • Expansion of Clinical Trials Across North America, Europe, and Asia Drives Globalization of Therapeutic Innovations
    • Strategic Collaborations Between Biotech Firms and Academic Institutions Accelerate Research and Commercialization Efforts
    • Improved Understanding of Immunopathogenesis of PBC Spurs Development of Immunomodulatory Therapies
    • Regulatory Incentives for Orphan Drug Designation Strengthen Pipeline Viability and Accelerate FDA/EMA Approvals
    • Rising Awareness Among Hepatologists and General Practitioners Drives Earlier Diagnosis and Therapeutic Intervention
    • Growth in Patient Advocacy and Rare Disease Networks Propels Demand for Innovative and Accessible Treatment Options
    • Focus on Quality-of-Life Improvements and Fatigue Management Enhances Therapeutic Value Proposition in Chronic PBC Care
    • Emergence of Combination Therapy Paradigms Drives Research in Multi-Targeted Treatment Approaches
    • Availability of Real-World Evidence and Post-Marketing Surveillance Strengthens Confidence in Long-Term Drug Safety
    • Expansion of Specialty Pharmacies and Targeted Distribution Models Sustains Market Access for High-Cost PBC Therapies
    • Challenges in Treatment Adherence and Side Effect Profiles Create Opportunities for Tolerability-Enhanced Formulations
    • Increased Integration of Genomic Data into Clinical Decision-Making Drives Precision Therapeutics in Hepatology
    • Growing Pipeline of Phase II and III Candidates Generates Optimism for Next-Generation PBC Treatment Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Biliary Cholangitis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Primary Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Secondary Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제